Immunome, Inc. (IMNM)
NASDAQ: IMNM · IEX Real-Time Price · USD
14.27
-0.39 (-2.66%)
Apr 24, 2024, 4:00 PM EDT - Market closed
Company Description
Immunome, Inc., a biotechnology company, develops targeted cancer therapies.
The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc.
Country | United States |
Founded | 2006 |
IPO Date | Oct 2, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 55 |
CEO | Dr. Clay B. Siegall Ph.D. |
Contact Details
Address: 18702 N. Creek Parkway, Suite 100 Bothell, Washington 98011 United States | |
Phone | 610-321-3700 |
Website | immunome.com |
Stock Details
Ticker Symbol | IMNM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $12.00 |
CIK Code | 0001472012 |
CUSIP Number | 45257U108 |
ISIN Number | US45257U1088 |
Employer ID | 77-0694340 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Clay B. Siegall Ph.D. | President, Chief Executive Officer and Chairman |
Max Rosett | Interim Chief Financial Officer and Executive Vice President of Operations |
Robert Lapetina | Principal Accounting Officer |
Philip Roberts | Chief Technical Officer |
Dr. Jack Higgins Ph.D. | Chief Scientific Officer |
Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel and Corporate Secretary |
Bruce Turner M.D., Ph.D. | Chief Strategy Officer |
Dr. Robert J. Lechleider M.D. | Chief Medical Officer |
Kinney Horn | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 3, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
Apr 3, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
Mar 28, 2024 | 10-K | Annual Report |
Mar 28, 2024 | 8-K | Current Report |
Mar 26, 2024 | 8-K | Current Report |
Feb 14, 2024 | 8-K | Current Report |
Feb 14, 2024 | 424B5 | Filing |
Feb 13, 2024 | 424B5 | Filing |
Feb 13, 2024 | 8-K | Current Report |
Feb 13, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |